The future of type 1 diabetes therapy

May combine two claims.

A randomised open-label study of 582 adults with type 1 diabetes showed noninferiority of insulin icodec to daily insulin degludec at 26 weeks of treatment, with better outcomes at 52 weeks of treatment, although more clinically significant hypoglycaemic events occurred with insulin icodec.

“A randomised openlabel study of 582 adults with type 1 diabetes showed noninferiority of insulin icodec to daily insulin degludec at 26 weeks of treatment, with better outcomes at 52 weeks of treatment, although more clinically significant hypoglycaemic events occurred with insulin icodec.87”

• cites [87] Russell-Jones, 2023, Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial, Lancet sourceDisputed

  Split into 2 atoms — 1 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Stage 1 is defined by the presence of at least two islet autoantibodies and normoglycaemia, and accounts for 80-90% of individuals with presymptomatic disease.

“Stage 1 is defined by the presence of at least two islet autoantibodies and normoglycaemia, and accounts for 80-90% of individuals with presymptomatic disease.8,12”

• cites [8] Ziegler, 2020, Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany, JAMA sourcePartly supported

  The Outcome Definitions section defines stage 1 as at least two islet autoantibodies with normal glucose tolerance. In Staging and Follow-up (page not provided), 196 of 239 children assigned a stage after screening were stage 1—about 82%. The paper does not establish that 80–90% of all individuals with presymptomatic disease are stage 1; its figure is limited to the children staged in this screening study. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [12] Hummel, 2025, Dysglycaemia definitions and progression to clinical type 1 diabetes in children with multiple islet autoantibodies, Lancet Diabetes Endocrinol sourceNot checked — no full text of the source

May combine two claims.

Early detection offers clinical benefits, such as statistically significant reductions in diabetic ketoacidosis and a milder onset of clinical diabetes.

“Although early detection offers clinical benefits, such as statistically significant reductions in diabetic ketoacidosis and a milder onset (ie, fewer symptoms and a lower degree of hyperglycaemia) of clinical diabetes, 13”

• cites [13] Hummel, 2023, Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation, Diabetologia sourcePartly supported

  The Results (Clinical presentation at diagnosis of stage 3 type 1 diabetes; page unavailable) show significantly lower HbA1c and fasting glucose in previously screened children, supporting a milder onset with less hyperglycaemia. The Results report DKA in only 2.5% of those children and symptoms in 43.8%, but do not report a statistically significant reduction in DKA or a comparison establishing fewer symptoms. The significant reduction reported is for ketonuria, which is not the same as DKA. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

One year of abatacept treatment for children and adolescents with stage 1 type 1 diabetes did not significantly delay progression to stage 2 or 3 (HR 0.70; 95% CI 0.45-1.09), but it preserved insulin secretion and modified immune cell subsets.

“Although 1 year of abatacept treatment for children and adolescents with stage 1 type 1 diabetes did not significantly delay progression to stage 2 or 3 (hazard ratio 0•70; 95% CI 0•45-1•09), it preserved insulin secretion and modified immune cell subsets.”

• cites [38] Russell, 2023, Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial, Diabetes Care sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

Post-hoc analyses identified subgroups with higher baseline C-peptide, lower insulin use, lower HbA1c, younger age, and shorter time since diagnosis who benefited most from teplizumab treatment, suggesting greater efficacy with early treatment in paediatric populations.

“Posthoc analyses identified subgroups with higher baseline Cpeptide measurement, lower insulin use, lower HbA₁ C , younger age, and shorter time since diagnosis who benefited most from teplizumab treatment, suggesting greater efficacy with early treatment in paediatric populations.34”

• cites [34] Hagopian, 2013, Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial, Diabetes sourceSupported

May combine two claims.

Two phase 2 trials of daily oral administration of 7.5 mg insulin in children with multiple autoantibodies showed no significant effect in delaying the onset of clinical diabetes; however, subgroup analyses showed a delay in disease progression in individuals with impaired insulin secretion, with the HLA DR4-DQ8 haplotype, or with high concentrations of insulin or IA2 autoantibodies.

“Two phase 2 trials evaluated daily oral administration of 7•5 mg insulin in children with multiple autoantibodies.40,41 Neither trial showed a significant effect in delaying the onset of clinical diabetes; however, subgroup analyses showed a delay in disease progression in individuals with impaired insulin secretion, with the HLA DR4DQ8 haplotype, or with high concentrations of insulin or IA2 auto”

• cites [40] Skyler, 2005, Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial—Type 1, Diabetes Care sourceNot checked — no full text of the source
• cites [41] Krischer, 2017, Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial, JAMA sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [49] Zhao, 2024, Oral insulin delay of stage 3 type 1 diabetes revisited in HLA DR4-DQ8 participants in the TrialNet oral insulin prevention trial (TN07), Diabetes Care sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

The earlier Protégé trial did not meet its primary composite endpoint of a significant difference in insulin dose and HbA1c at 1 year; however, teplizumab treatment reduced the loss of C-peptide response to a standard mixed meal at 2 years.

“The earlier Protégé trial, 33,34 which included children and adults, did not meet its primary composite endpoint of a significant difference in the insulin dose and glycated haemoglobin (HbA₁ c ) concentrations at 1 year; however, teplizumab treatment reduced the loss of Cpeptide response to a standard mixed meal, a prespecified secondary endpoint, at 2 years.34”

• cites [33] Sherry, 2011, Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial, Lancet sourceSupported
• cites [34] Hagopian, 2013, Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial, Diabetes sourceSupported

May combine two claims.

A very recent trial assessing the efficacy and safety of low-dose ATG showed that β-cell function can be preserved with doses lower than previously considered effective and that the therapy is safe in children 5 years or older.

“A very recent trial assessing the efficacy and safety of lowdose ATG showed that βcell function can be preserved with doses lower than previously considered effective and that the therapy is safe in children 5 years or older.22”

• cites [22] Mathieu, 2025, Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial, Lancet sourceSupported

May combine two claims.

Two early stages of type 1 diabetes are defined, and each is associated with distinct rates of progression to clinical diabetes.

“Two early stages of type 1 diabetes are defined, and each is associated with distinct rates of progression to clinical diabetes (figure 1).[9][10][11]”

• cites [9] Haller, 2024, ISPAD Clinical Practice Consensus Guidelines 2024: screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes, Horm Res Paediatr sourceSupported
• cites [10] ElSayed, 2025, 2. Diagnosis and classification of diabetes: standards of care in diabetes—2025, Diabetes CareNot checked yet

  Not checked in the free run.

• cites [11] Phillip, 2024, Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes, Diabetes CareNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

Stage 2 is defined by positive islet autoantibodies accompanied by dysglycaemia.

“Stage 2 is defined by positive islet autoantibodies accompanied by dysglycaemia.8,12”

• cites [8] Ziegler, 2020, Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany, JAMA sourcePartly supported

  The Outcome Definitions section defines stage 2 as dysglycemia accompanied by two or more islet autoantibodies. The claim captures the dysglycemia requirement but omits the minimum of two autoantibodies, an essential part of the definition. No page number is provided for the passage. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [12] Hummel, 2025, Dysglycaemia definitions and progression to clinical type 1 diabetes in children with multiple islet autoantibodies, Lancet Diabetes Endocrinol sourceNot checked — no full text of the source

May combine two claims.

Faster-acting insulin aspart has a quicker onset and offset than regular insulin aspart and offers better control of postmeal glucose spikes and less hypoglycaemia 2-5 h after a meal.

“Fasteracting insulin aspart has a quicker onset and offset than regular insulin aspart and offers better control of postmeal glucose spikes and less hypoglycaemia 2-5 h after a meal.80”

• cites [80] Heise, 2017, A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes, Clin Pharmacokinet sourcePartly supported

  The Conclusions report faster onset and earlier offset than insulin aspart, and the Discussion reports better postprandial glucose control in meal tests. The Discussion says earlier offset may reduce late postprandial hypoglycaemia, but it does not establish less hypoglycaemia 2–5 hours after a meal. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

This finding aligns with those of previous clinical trials that showed faster-acting insulins improve postprandial glucose without compromising overall glycaemic management or safety.

“This finding aligns with those of previous clinical trials that showed fasteracting insulins improve postprandial glucose without compromising overall glycaemic management or safety.80,81”

• cites [80] Heise, 2017, A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes, Clin Pharmacokinet sourceSupported
• cites [81] Wadwa, 2023, Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: the PRONTO-Peds trial, Diabetes Obes Metab sourcePartly supported

  The Results (Efficacy) and Discussion report that mealtime ultra-rapid lispro improved postprandial glucose versus lispro while remaining noninferior for HbA1c in children and adolescents with type 1 diabetes. The Results (Safety) report similar overall rates of severe and documented hypoglycaemia, but higher early postdose hypoglycaemia and more injection-site reactions with mealtime ultra-rapid lispro. Thus, the unqualified claim that safety was not compromised overlooks reported safety differences. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Treatment with pleconaril together with ribavirin temporarily preserves β-cell function more effectively than placebo; however, the benefit was not found to be present after 2 years and after 3 years.

“Treatment with the viral clearing agent pleconaril, together with the broadspectrum antiviral drug ribavirin, temporarily preserves βcell function more effectively than placebo (table 1); 29 however, the benefit was not found to be present after 2 years and after 3 years.30”

• cites [29] Krogvold, 2023, Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial, Nat Med sourceSupported
• cites [30] Mynarek, 2025, Three-year follow-up after antiviral treatment in new-onset type 1 diabetes: results from the diabetes virus detection and intervention trial, Diabetes Care sourceNot checked — no full text of the source

May combine two claims.

Approximately 1 billion pancreatic progenitor cells are estimated to be required per person, although this number could be less if more mature cells are used.

“Approximately 1 billion pancreatic progenitor cells are estimated to be required per person, although this number could be less if more mature cells are used.”

• cites [78] Verhoeff, 2025, Scalable bioreactor-based suspension approach to generate stem cell-derived islets from healthy donor-derived iPSCs, Transplantation sourceNot checked — no full text of the source
• cites [79] Yehya, 2024, Identifying and optimizing critical process parameters for large-scale manufacturing of iPSC derived insulin-producing β-cells, Stem Cell Res Ther sourcePartly supported

  The Discussion estimates that around 1 billion β-cells are needed to treat a patient with type 1 diabetes. It does not give that estimate for pancreatic progenitor cells or say that using more mature cells could reduce the number required. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

GAD65-based therapies delivered via subcutaneous or intralymphatic administration have been tested in multiple clinical trials; overall efficacy in preserving insulin secretion was not shown.

“GAD₆₅based therapies delivered via subcutaneous or intralymphatic administration have been tested in multiple clinical trials.[24][25][26] Overall efficacy in preserving insulin secretion was not shown.”

• cites [24] Ludvigsson, 2008, GAD treatment and insulin secretion in recent-onset type 1 diabetes, N Engl J Med sourcePartly supported

  The Methods describe one trial of subcutaneous GAD-alum injections; this paper does not test intralymphatic administration. The Results report no significant effect on the 15-month primary endpoint, but significantly less decline in insulin secretion at 30 months, so an unqualified statement that preservation was not shown overstates this source. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [25] Wherrett, 2011, Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial, Lancet sourcePartly supported

  The Methods (Procedures) describe subcutaneous GAD-alum injections, and the Results (Efficacy) found no significant difference in C-peptide preservation versus placebo. The Discussion mentions an earlier GAD-alum study, but this paper does not test intralymphatic administration or establish an overall efficacy conclusion across both routes. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [26] Ludvigsson, 2021, Intralymphatic glutamic acid decarboxylase with vitamin D supplementation in recent-onset type 1 diabetes: a double-blind, randomized, placebo-controlled phase IIb trial, Diabetes Care sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Stem cells begin as proliferative undifferentiated cells that are exposed to a series of cycles of growth and differentiation factors that lead to seven defined stages.

“These stem cells begin as proliferative undifferentiated cells that are exposed to a series of cycles of growth and differentiation factors that lead to seven defined stages.”

• cites [68] Pagliuca, 2014, Generation of functional human pancreatic β cells in vitro, Cell sourcePartly supported

  The Experimental Procedures (Cell culture; page not provided) begin with undifferentiated human pluripotent stem cells and describe successive changes in differentiation media. The Results (Generation of Glucose-Sensing Insulin-Secreting β Cells In Vitro; page not provided) also describe sequential culture steps using growth factors and other signaling agents. Our copy does not establish the claimed count of seven defined stages. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [69] Rezania, 2014, Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells, Nat Biotechnol sourceNot checked — no full text of the source

May combine two claims.

Controlled trials and follow-up of recipients in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen.

“Controlled trials 62,63 and followup of recipients 64,65 in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen; however,”

• cites [62] Hering, 2016, Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia, Diabetes Care sourceNot checked — no full text of the source
• cites [63] Lablanche, 2018, Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial, Lancet Diabetes Endocrinol sourceNot checked — no full text of the source
• cites [64] Chetboun, 2023, Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry, Lancet Diabetes Endocrinol sourceSupported
• cites [65] Marfil-Garza, 2022, Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada, Lancet Diabetes Endocrinol sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

In this study, the cells were transplanted into the rectus sheath in the anterior abdominal wall.

“In this study, the cells were transplanted into the rectus sheath in the anterior abdominal wall (table 3).72”

• cites [72] Wang, 2024, Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient, Cell sourceSupported

May combine two claims.

One approach to reduce immunosuppression is to use encapsulation within devices that exclude immune cells from direct interaction with transplanted cells, which is a bioengineering challenge for which high oxygen tension is required.

“One approach is to use encapsulation within devices that exclude immune cells from direct interaction with transplanted cells, 73 which is a bioengineering challenge for which high oxygen tension is required.”

• cites [73] Grattoni, 2025, Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead, Nat Rev Endocrinol sourceSupported

May combine two claims.

SPK is highly effective despite the initial risk of perioperative morbidity, with insulin independence and patient survival at high rates according to registry data.

“This procedure is highly effective despite the initial risk of perioperative morbidity (eg, pancreatic vascular thrombosis), with insulin independence and patient survival at high rates according to registry data.58”

• cites [58] Rickels, 2025, Islet transplantation versus standard of care for type 1 diabetes complicated by severe hypoglycemia from the Collaborative Islet Transplant Registry and the T1D Exchange Registry, Diabetes Care sourcePartly supported

  The Abstract reports that a majority of recipients in the Collaborative Islet Transplant Registry were insulin independent, supporting that outcome for islet transplantation. The paper studies islet transplantation, not simultaneous pancreas–kidney transplantation (SPK); its reported risks concern kidney function and immunosuppression, not perioperative pancreatic vascular thrombosis. It does not report the claimed high patient-survival rate for SPK. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Liraglutide improved residual β-cell function and reduced insulin requirements in people with adult-onset type 1 diabetes during the first year post-diagnosis.

“Similarly, liraglutide improved residual βcell function and reduced insulin requirements in people with adultonset type 1 diabetes during the first year postdiagnosis.50”

• cites [50] Dejgaard, 2024, Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial, Diabetes Obes Metab sourceSupported

May combine two claims.

Treating many people with type 1 diabetes will require substantial scale-up of cell manufacturing and other changes, such as potentially shortening the duration of in-vitro steps to reduce cost and increase efficiency.

“Treating many people with type 1 diabetes will require substantial scaleup of cell manufacturing and other changes, such as potentially shortening the duration of invitro steps to reduce cost and increase efficiency.78,79”

• cites [78] Verhoeff, 2025, Scalable bioreactor-based suspension approach to generate stem cell-derived islets from healthy donor-derived iPSCs, Transplantation sourceNot checked — no full text of the source
• cites [79] Yehya, 2024, Identifying and optimizing critical process parameters for large-scale manufacturing of iPSC derived insulin-producing β-cells, Stem Cell Res Ther sourcePartly supported

  The Background and Discussion support the need to scale up manufacturing to produce enough cells for type 1 diabetes treatment. But the Discussion reports that extending differentiation stages improved desired markers and proposes reducing media replenishment to offset the added cost; it does not support shortening the in-vitro stages as the efficiency measure. (LLM, conf=0.89)

  Experimental — accuracy not yet measured

May combine two claims.

The first four stages produce proliferative cells; as the cells differentiate, they become less proliferative.

“The first four stages produce proliferative cells.As the cells differentiate, they become less proliferative.”

• cites [68] Pagliuca, 2014, Generation of functional human pancreatic β cells in vitro, Cell sourceCould not verify

  The Results section describes pancreatic progenitors differentiating into β-like cells, and Experimental Procedures > Cell culture lists the stages of the protocol (page numbers unavailable). Neither reports that cells in the first four stages are proliferative or that proliferation declines with differentiation; searches for “proliferative,” “proliferation,” and cell-cycle terms found no such comparison. (LLM, conf=0.74)

  Experimental — accuracy not yet measured
• cites [69] Rezania, 2014, Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells, Nat Biotechnol sourceNot checked — no full text of the source

May combine two claims.

Islet transplantation reduced mortality compared with kidney transplants and composite negative outcomes including mortality in individuals without kidney transplants.

“and islet transplantation reduced mortality compared with kidney transplants and composite negative outcomes including mortality in individuals without kidney transplants.66,67”

• cites [66] Maanaoui, 2024, Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France, Lancet Diabetes Endocrinol sourceSupported
• cites [67] Perrier, 2025, Impact of islet transplantation on diabetes complications and mortality in patients living with type 1 diabetes, Diabetes Care sourcePartly supported

  The Results (Table 2; page not supplied) show lower mortality for islet-transplant-alone recipients than for their controls without kidney transplants, and lower composite-outcome risk in both study groups. But mortality was not significantly lower for islet-after-kidney recipients than for kidney-transplant-only controls (HR 0.78, 95% CI 0.38–1.61; P = 0.50). The claim assigns the mortality finding to the wrong comparator. (LLM, conf=0.91)

  Experimental — accuracy not yet measured

May combine two claims.

Additional steps can also be applied, including reduction in major histocompatibility complex class II expression, protection from natural killer cells, and protection from cytokines.

“Additional steps can also be applied, including reduction in major histocompatibility complex class II expression, protection from natural killer cells, and protection from cytokines.”

• cites [75] Sackett, 2022, Genetic engineering of immune evasive stem cell-derived islets, Transpl Int sourcePartly supported

  The genetic-modifications sections (pages unavailable in our copy) describe reducing MHC class II expression and engineering protection from natural killer cells. The Mechanisms of Islet Destruction section proposes ways to reduce responses to cytokine-related inflammation, but says protection of stem cell-derived islets by cytokine inhibitors has not been studied; it does not establish that this protection can be applied. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

Natural history studies, intervention trials, and transplantation studies consistently show that higher C-peptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced long-term complications.

“natural history studies, intervention trials, and transplantation studies consistently show that higher Cpeptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced longterm complications.[55][56][57]”

• cites [55] Latres, 2024, Evidence for C-peptide as a validated surrogate to predict clinical benefits in trials of disease-modifying therapies for type 1 diabetes, Diabetes sourceNot checked — no full text of the source
• cites [56] Evans-Molina, 2024, A golden hour and golden opportunity for β-cell preservation, Diabetes sourcePartly supported

  In the section discussing DCCT/EDIC and the intervention-trial evidence (page not provided), the paper links preserved C-peptide with improved glycaemic control and describes indirect evidence for fewer hypoglycaemic episodes and complications. It says hypoglycaemia was inconsistently measured across trials, so the claim overstates how consistently all three study types show all three outcomes. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [57] Steffes, 2003, Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial, Diabetes Care sourcePartly supported

  The study reports that higher or sustained mixed-meal-stimulated C-peptide was associated with lower mean HbA1c (Results, p. 2), fewer severe hypoglycaemic episodes, and less retinopathy and nephropathy (opening summary, p. 1). It is a retrospective analysis of DCCT participants, however, and does not establish the claimed consistency across natural history, intervention, and transplantation studies. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Additional novel formulations are being investigated in animal studies.

“and additional novel formulations are being investigated in animal studies.83”

• cites [83] Mann, 2020, An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients, Sci Transl Med sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Although no TITR goal has been universally established, a TITR of higher than 50% is considered a reasonable target.

“Although no TITR goal has been universally established, a TITR of higher than 50% is considered a reasonable target (figure 3B). 100”

• cites [100] de Bock, 2024, International Society for Pediatric and Adolescent Diabetes clinical practice consensus guidelines 2024: glycemic targets, Horm Res Paediatr sourceSupported

May combine two claims.

Clinical trials and real-world data have shown that AID systems effectively reduce HbA1c, time above range, and time below range, and increase time in range by an average of 10-15 percentage points when compared with standard care.

“Clinical trials and realworld data have shown that AID systems effectively reduce HbA₁ c , time above range, and time below range, and increase time in range by an average of 10-15 percentage points when compared with standard care.”

• cites [100] de Bock, 2024, International Society for Pediatric and Adolescent Diabetes clinical practice consensus guidelines 2024: glycemic targets, Horm Res Paediatr sourcePartly supported

  In The Purpose of Setting Glycemic Targets (page not provided), the guideline identifies AID implementation as one contributor to improved population glycemic metrics. It does not report the claimed reductions in HbA1c, time above range, or time below range versus standard care, or a 10–15-percentage-point increase in time in range. The Glycated Hemoglobin section instead directs readers to a separate guideline for evidence on the efficacy of advanced technologies. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Alternative routes of insulin delivery, such as intraperitoneal insulin and the addition of premeal inhaled insulin (Afrezza) to AID systems, are being investigated.

“Alternative routes of insulin delivery, such as intraperitoneal insulin and the addition of premeal inhaled insulin (Afrezza) to AID systems, are being investigated.106”

• cites [106] Galderisi, 2020, Effect of afrezza on glucose dynamics during HCL treatment, Diabetes Care sourcePartly supported

  The Objective and Research Design and Methods sections describe a study of premeal inhaled Afrezza during hybrid closed-loop insulin delivery. The passages provide no support for the intraperitoneal-insulin example; a search for that term found no relevant passage. Page numbers were not available in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Although stem-cell therapy has shown remarkable results in a few people, its promise as a therapy for broad application is dependent on the safe engineering of cells that avoid both alloimmunity and autoimmunity, and on production methods that meet the global demand for cell-based therapy at affordable costs.

“Although stemcell therapy has shown remarkable results in a few people, 71,72 its promise as a therapy for broad application is dependent on the safe engineering of cells that avoid both alloimmunity and autoimmunity, and on production methods that meet the global demand for cellbased therapy at affordable costs.”

• cites [71] Reichman, 2025, Stem cell-derived, fully differentiated islets for type 1 diabetes, N Engl J Med sourceNot checked — no full text of the source
• cites [72] Wang, 2024, Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient, Cell sourceSupported

May combine two claims.

Metformin improves insulin sensitivity and cardiovascular outcomes in people with type 1 diabetes.

“Metformin improves insulin sensitivity and cardiovascular outcomes in people with type 1 diabetes.91,92”

• cites [91] Cree-Green, 2019, Metformin improves peripheral insulin sensitivity in youth with type 1 diabetes, J Clin Endocrinol Metab sourcePartly supported

  The Discussion reports improved whole-body and peripheral insulin sensitivity in adolescents with overweight or obesity and type 1 diabetes. The paper does not report improved cardiovascular outcomes in that group; its Abstract discusses reduced cardiovascular risk and mortality with metformin in adults with type 2 diabetes. The claim also generalizes the insulin-sensitivity finding beyond the youth studied. (LLM, conf=0.89)

  Experimental — accuracy not yet measured
• cites [92] Cengiz, 2024, International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: insulin and adjunctive treatments in children and adolescents with diabetes, Horm Res Paediatr sourceCould not verify

  The available passages labeled Abstract contain bibliographic information and list metformin as a keyword, but do not discuss its effects. Searches for improved insulin sensitivity and cardiovascular outcomes in type 1 diabetes returned no substantive passage, so the claim cannot be verified from our copy. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

May combine two claims.

The improvement in time in range and the reduction in HbA1c with AID systems were found with no increase (and in some cases, a reduction) in hypoglycaemia across all age groups.

“This improvement in time in range and the reduction in HbA₁ c were found with no increase (and in some cases, a reduction) in hypoglycaemia across all age groups. 100”

• cites [100] de Bock, 2024, International Society for Pediatric and Adolescent Diabetes clinical practice consensus guidelines 2024: glycemic targets, Horm Res Paediatr sourcePartly supported

  The Abstract says that lower HbA1c targets can be achieved without increasing hypoglycemia risk when adequate technology and professional support are available. The Continuous Glucose Monitoring section sets time-in-range targets, but our copy does not report that AID improved time in range, reduced hypoglycemia in some cases, or produced these outcomes across all age groups. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

GLP-1 receptor agonists reduce bodyweight and insulin dose, with modest improvements in glycaemic control.

“GLP1 receptor agonists reduce bodyweight and insulin dose, with modest improvements in glycaemic control.[93][94][95][96]”

• cites [93] Mathieu, 2016, Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial, Diabetes Care sourceNot checked — no full text of the source
• cites [94] Ahrén, 2016, Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial, Diabetes Care sourceNot checked — no full text of the source
• cites [95] Shah, 2025, Consensus report on glucagon-like peptide-1 receptor agonists as adjunctive treatment for individuals with type 1 diabetes using an automated insulin delivery system, J Diabetes Sci Technol sourceSupported
• cites [96] Pasqua, 2025, Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial, Nat Med sourcePartly supported

  The Discussion reports that semaglutide reduced body weight and insulin requirements and improved glycaemic control in adults with type 1 diabetes using automated insulin delivery. The claim generalizes those findings to GLP-1 receptor agonists as a class; this trial directly tested only semaglutide in that specific setting. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Only one AID system is approved for use during pregnancy, and it has been shown to improve time in the target glucose range of 3.5-7.8 mmol/L without increasing the risk of hypoglycaemia.

“Only one AID system is approved for use during pregnancy, and it has been shown to improve time in the target glucose range of 3•5-7•8 mmol/L without increasing the risk of hypoglycaemia.104”

• cites [104] Lee, 2023, Automated insulin delivery in women with pregnancy complicated by type 1 diabetes, N Engl J Med sourcePartly supported

  The Methods (p. 2) define the pregnancy-specific target as 3.5–7.8 mmol/L; the Primary Outcome (p. 10) reports more time in that range with closed-loop therapy, and Secondary Glycemic Outcomes (p. 10) reports no additional hypoglycemia. The paper says CamAPS FX was approved for pregnancy use in the United Kingdom (p. 3), but does not establish that it was the only approved AID system. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

In adults aged 18-30 years with suboptimal glycaemic control, sotagliflozin plus insulin for 12 weeks improved HbA1c, postprandial blood sugar, goal attainment, and bodyweight.

“In adults aged 18-30 years with suboptimal glycaemic control, sotagliflozin plus insulin for 12 weeks improved HbA₁ c , postprandial blood sugar, goal attainment, and bodyweight.97”

• cites [97] Bode, 2021, Effects of sotagliflozin combined with intensive insulin therapy in young adults with poorly controlled type 1 diabetes: the JDRF sotagliflozin study, Diabetes Technol Ther sourcePartly supported

  The Abstract describes adults aged 18–30 treated for 12 weeks and reports improved postprandial glucose, A1C goal attainment, and body weight. It describes the overall A1C improvement as numerical: the difference from placebo was not statistically significant (P = 0.10). The Discussion likewise limits its conclusion to a numerical A1C reduction, so the unqualified HbA1c claim overstates that result. (LLM, conf=0.89)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Of individuals identified with presymptomatic diabetes, approximately 85% have stage 1 and 15% stage 2.

“Of individuals identified with presymptomatic diabetes, approximately 85% have stage 1 and 15% stage 2.4”

• cites [4] Russell-Jones, 2023, Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial, Lancet sourceCould not verify

  The Study design and participants section describes adults with established type 1 diabetes who had received insulin injections for at least a year. The Results section reports treatment-group outcomes, not the distribution of presymptomatic diabetes stages. Searches for presymptomatic diabetes and stage 1/stage 2 found no passage supporting the 85%/15% figures; page numbers were not available in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

Afrezza is the fastest-acting exogenous insulin due to rapid absorption from the lungs, and eliminates the delays seen with subcutaneous injection.

“Afrezza (MannKind, Danbury, CT, USA), a human insulin inhaled powder, is the fastestacting exogenous insulin due to rapid absorption from the lungs, and eliminates the delays seen with subcutaneous injection.84”

• cites [84] Grant, 2022, Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus, Clin Pharmacokinet sourcePartly supported

  The Conclusions (page unavailable) say inhaled Technosphere Insulin, sold as Afrezza, has a faster onset than subcutaneous lispro. But they place its time-action profile between IV bolus and subcutaneous insulin; the Introduction reports IV insulin reaching peak concentration sooner. The claim that Afrezza is the fastest-acting exogenous insulin and eliminates injection-related delays therefore overstates the paper's findings. (LLM, conf=0.89)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S4 (based).

Public health screening using islet autoantibodies is expanding.

“Public health screening using islet autoantibodies is expanding, enabling earlier diagnosis, reducing diabetic ketoacidosis, and allowing timely introduction of diseasemodifying treatments before the need for insulin therapy.”

May combine two claims.

Side-effects of teplizumab include transient lymphopenia, rash, headache, gastrointestinal symptoms, transient liver transaminase elevation, nausea, and mild cytokine release syndrome.

“Sideeffects of teplizumab include transient lymphopenia, rash, headache, gastrointestinal symptoms, transient liver transaminase elevation, nausea, and mild cytokine release syndrome.”

May combine two claims.

Compared with teplizumab, some other immunotherapies not only preserve residual β-cell function, but also reduce insulin requirements and improve glycaemic control, without significant adverse events.

“Compared with teplizumab, some of these therapies not only preserve residual βcell function, but also reduce insulin requirements and improve glycaemic control, without significant adverse events (table 1).”

• cites [23] Waibel, 2023, Baricitinib and β-cell function in patients with new-onset type 1 diabetes, N Engl J Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). The quote only partly states this claim.

New-generation insulins (ultrarapid, ultralong, and glucose-responsive) improve outcomes by minimising blood sugar fluctuations.

“Ultrarapid-acting insulins offer improved post-meal control and improved performance in automated insulin delivery (AID) systems.”

May combine two claims.

The combination of anti-IL21 and liraglutide preserved C-peptide after 1 year of treatment but led to greater insulin secretion loss after treatment cessation compared with placebo.

“The combination of antiIL21 and liraglutide preserved Cpeptide after 1 year of treatment but led to greater insulin secretion loss after treatment cessation compared with placebo.51”

• cites [51] von Herrath, 2021, Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Diabetes Endocrinol sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S4 (based).

A limitation of clinical trials conducted to date is that most were done in small participant populations.

“A limitation of clinical trials conducted to date is that most were done in small participant populations.”

Classified as probably not a substantial claim.

Immunotherapy has the potential to reshape the future of type 1 diabetes care by complementing and preceding traditional insulin therapy.

“By intervening in the disease process, immunotherapy has the potential to reshape the future of type 1 diabetes care by complementing and preceding traditional insulin therapy.”

Probably not a substantial claim: may not pass S4 (based).

Other immune-based therapies show promise in preserving β-cell function.

“Other immunebased therapies show promise in preserving β-cell function.”

Classified as probably not a substantial claim. May combine two claims.

Teplizumab targets CD3, a component of the T-cell receptor complex crucial for activating CD4+ and CD8+ T cells, which play a key role in the destruction of pancreatic β cells.

“Teplizumab targets CD3, a component of the Tcell receptor complex crucial for activating CD4 + and CD8 + T cells, which play a key role in the destruction of pancreatic β cells.”

May combine two claims.

Early detection of type 1 diabetes by islet autoantibodies has been widely practised in relatives of individuals with type 1 diabetes and is now recommended by American Diabetes Association guidelines.

“Early detection of type 1 diabetes by islet autoantibodies has been widely practised in relatives of individuals with type 1 diabetes and is now recommended by American Diabetes Association guidelines.10”

• cites [10] ElSayed, 2025, 2. Diagnosis and classification of diabetes: standards of care in diabetes—2025, Diabetes CareNot checked yet

  Not checked in the free run.

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

Although approved for other indications, these therapies have not yet received regulatory approval for type 1 diabetes, as in most cases, pivotal regulatory approval studies are still outstanding.

“Although approved for other indications, these therapies have not yet received regulatory approval for type 1 diabetes, as in most cases, pivotal regulatory approval studies are still outstanding.”

May combine two claims.

For those with newly established clinical disease, combining immunotherapy with insulin can help preserve residual β-cell function, slow disease progression, and improve metabolic outcomes.

“For those with newly established clinical disease, combining immunotherapy with insulin can help preserve residual βcell function, slow disease progression, and improve metabolic outcomes (panel 1).”

Probably not a substantial claim: may not pass S4 (based).

β-cell replacement is shifting from traditional transplantation of organ donor islets and the pancreas to stem cell-derived β cells.

“β-cell replacement is shifting from traditional transplantation of organ donor islets and the pancreas to stem cell-derived β cells.”

Probably not a substantial claim: may not pass S4 (based).

Bioengineering methods, such as encapsulation, and gene editing to create hypoimmune cells could reduce the need for immunosuppression that has hampered β-cell replacement.

“Bioengineering methods, such as encapsulation, and gene editing to create hypoimmune cells could reduce the need for immunosuppression that has hampered β-cell replacement, and patient-derived stem cells open doors to personalised therapies.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

Patient-derived stem cells open doors to personalised therapies.

“Bioengineering methods, such as encapsulation, and gene editing to create hypoimmune cells could reduce the need for immunosuppression that has hampered β-cell replacement, and patient-derived stem cells open doors to personalised therapies.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Scaling these innovations to widespread use remains a challenge.

“Although these innovations have been made available to a small number of patients, scaling them to widespread use remains a challenge.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

Long recruitment periods lead to inflated costs, which deter pharmaceutical companies from pursuing these studies.

“Long recruitment periods lead to inflated costs, which deter pharmaceutical companies from pursuing these studies.”

May combine two claims.

Now, cells are grown in suspension cultures that produce more cells with better potential for transplantation.

“Now, cells are grown in suspension cultures that produce more cells with better potential for transplantation.”

May combine two claims.

Islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.

“Nevertheless, islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.62”

• cites [62] Hering, 2016, Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia, Diabetes Care sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

A challenge in reducing immunosuppression is the absence of models to test protection from preexisting memory autoimmune responses, whereas protection from alloimmunity can be tested in primate studies.

“A challenge in reducing immunosuppression is the absence of models to test protection from preexisting memory autoimmune responses, whereas protection from alloimmunity can be tested in primate studies.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

A biological licence was issued by US FDA to CellTrans in June, 2023, but is yet to have a major effect on islet transplant numbers.

“A biological licence was issued by US FDA to CellTrans in June, 2023, but is yet to have a major effect on islet transplant numbers.”

May combine two claims.

Two deaths occurred in the Vertex-880 trial, neither of which were related to the procedure or the cells.

“Two deaths occurred, neither of which were related to the procedure or the cells.”

• cites [71] Reichman, 2025, Stem cell-derived, fully differentiated islets for type 1 diabetes, N Engl J Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Side-effects of immunosuppression include the nephrotoxicity of calcineurin inhibitors.

“the sideeffects of immunosuppression, including the nephrotoxicity of calcineurin inhibitors;”

May combine two claims.

This risk is mitigated by reducing the time in culture to reduce karyotype abnormalities and monitoring for these, and by separating cells into populations associated with later stages of differentiation.

“This risk is mitigated by reducing the time in culture to reduce karyotype abnormalities and monitoring for these, and by separating cells into populations associated with later stages of differentiation.”

May combine two claims.

Limitations of islet transplantation include the marginal nature of β-cell replacement with vulnerability to loss of graft function from alloimmunity, autoimmunity, or drug toxicity resulting in loss of insulin independence over time.

“These limitations include the marginal nature of the βcell replacement with vulnerability to loss of graft function from alloimmunity, autoimmunity, or drug toxicity resulting in loss of insulin independence over time;”

Probably not a substantial claim: may not pass S3 (load-bearing).

Another approach is encapsulation to contain transplanted cells.

“Another approach is encapsulation to contain transplanted cells.”

May combine two claims.

SPK continues to be the standard of care with kidney transplantation due to it frequently resulting in insulin independence when the whole pancreas is transplanted, the fact that the recipients already need to take immunosuppression, and the improved survival compared with kidney transplant alone.

“SPK continues to be the standard of care with kidney transplantation due to it frequently resulting in insulin independence when the whole pancreas is transplanted, the fact that the recipients already need to take immunosuppression, and the improved survival compared with kidney transplant alone.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Stem cells can either be derived from embryonic stem cell lines or induced pluripotent stem cells made from dedifferentiation of mature cells.

“The stem cells can either be derived from embryonic stem cell lines or induced pluripotent stem cells made from dedifferentiation of mature cells.”

May combine two claims.

In children and adolescents with type 1 diabetes, mealtime and postmeal faster-acting insulin aspart combined with insulin degludec provided effective glycaemic control compared with insulin aspart in a 26-week clinical trial, with no safety concerns.

“In children and adolescents with type 1 diabetes, mealtime and postmeal fasteracting insulin aspart combined with insulin degludec provided effective glycaemic control compared with insulin aspart in a 26week clinical trial, with no safety concerns.”

May combine two claims.

In the Vertex 264 phase 1 clinical trial, cells were transplanted within a proprietary encapsulation device; however, this trial did not meet its primary endpoint.

“In the Vertex 264 phase 1 clinical trial, cells were transplanted within a proprietary encapsulation device; however, this trial did not meet its primary endpoint.70”

• cites [70] Kieffer, 2025, Advances in islet transplantation and the future of stem cell-derived islets to treat diabetes, Cold Spring Harb Perspect Med sourceNot checked — no full text of the source

May combine two claims.

The observed differences are sometimes marginal and not sustained beyond the treatment period, which suggests that medications might need to be administered continuously to maintain their effects.

“Moreover, the observed differences are sometimes marginal and not sustained beyond the treatment period, which suggests that medications might need to be administered continuously to maintain their effects.”

May combine two claims.

The cost of production is estimated to be in the hundreds of thousands of US dollars per person, but this cost could decrease, as the cost of goods is less for an off-the-shelf embryonic stem cell-derived product rather than a personalised product from induced pluripotent stem cells.

“The cost of production is estimated to be in the hundreds of thousands of US dollars per person, but this cost could decrease, as the cost of goods is less for an offtheshelf embryonic stem cellderived product rather than a personalised product from induced pluripotent stem cells.”

May combine two claims.

When the device was modified to allow vessel entry, the cells survived, and C-peptide was measurable with an effect on glucose control and insulin requirement.

“When the device was modified to allow vessel entry, the cells survived, and Cpeptide was measurable with an effect on glucose control and insulin requirement.”

• cites [70] Kieffer, 2025, Advances in islet transplantation and the future of stem cell-derived islets to treat diabetes, Cold Spring Harb Perspect Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Until approximately 5 years ago, cells were grown in conventional 2D cultures that required large numbers of culture flasks.

“Until approximately 5 years ago, cells were grown in conventional 2D cultures that required large numbers of culture flasks.”

May combine two claims.

Vertex-880 is an off-the-shelf embryonic stem cell-derived product consisting of differentiated post-mitotic β cells delivered into the portal vein and protected from alloimmune and autoimmune attack by conventional immunosuppression.

“This offtheshelf embryonic stem cellderived product consists of differentiated post mitotic β cells delivered into the portal vein and protected from alloimmune and autoimmune attack by conventional immuno suppression.”

• cites [71] Reichman, 2025, Stem cell-derived, fully differentiated islets for type 1 diabetes, N Engl J Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Suicide switches, such as thymidine kinase, that can be activated after transplantation are also possible.

“Socalled suicide switches, such as thymidine kinase, that can be activated, if necessary, after transplantation are also possible.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

In Europe, access to health care might be generally more equitable due to universal healthcare systems.

“In Europe, access to health care might be generally more equitable due to universal healthcare systems.”

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

Access to teplizumab and similar disease-modifying therapies will largely depend on their cost and whether these therapies are covered by public or private health insurance.

“Access to teplizumab and similar diseasemodifying therapies will largely depend on their cost and whether these therapies are covered by public or private health insurance.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

Continuous glucose monitors provide trend data that inform insulin treatment and reflect the effects of lifestyle decisions, including dietary choices, activity, stress, and many other factors, on glycaemia.

“Continuous glucose monitors provide trend data that inform insulin treatment and reflect the effects of lifestyle decisions, including dietary choices, activity, stress, and many other factors, on glycaemia.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Next-generation AID systems consist of smart insulin pumps equipped with insulin delivery algorithms and continuous glucose monitoring interfaces.

“Nextgeneration AID systems consist of smart insulin pumps equipped with insulin delivery algorithms and continuous glucose monitoring interfaces.”

May combine two claims.

Insulin action can be delayed and vary between individuals and with different insulin analogues, which limits the ability of the AID system to respond promptly to rising glucose concentrations.

“Insulin action can be delayed and vary between individuals and with different insulin analogues, which limits the ability of the AID system to respond promptly to rising glucose concentrations.105”

• cites [105] Cengiz, 2016, Moving toward the ideal insulin for insulin pumps, Expert Rev Med Devices sourceNot checked — no full text of the source

May combine two claims.

Studies involving ultrarapid insulins used in conjunction with hybrid AID systems have not consistently shown significant improvements in time in range, which highlights the need for the development of novel ultrarapid-acting insulins.

“Studies involving ultrarapid insulins used in conjunction with hybrid AID systems have not consistently shown significant improvements in time in range, which highlights the need for the development of novel ultrarapidacting insulins.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Research is ongoing regarding various GRI formulations, and GRIs are not clinically available for treatment of diabetes.

“Research is ongoing regarding various GRI formulations, and GRIs are not clinically available for treatment of diabetes.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Research is exploring multihormone AID systems, which involve the combined use of insulin with glucagon or pramlintide, either through separate infusions or as a coformulation.

“Research is exploring multihormone AID systems, which involve the combined use of insulin with glucagon or pramlintide, either through separate infusions or as a coformulation.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

Some data suggest that providing the system with information about the macronutrient amount of meals can have a favourable effect on postprandial glycaemia.

“Some data suggest that providing the system with information about the macronutrient amount of meals can have a favourable effect on postprandial glycaemia.”

May combine two claims.

The efficacy of pramlintide is modest, with an average HbA1c reduction of 0.2-0.4% and average weight loss of approximately 0.5-1 kg.

“The efficacy of pramlintide is modest, with an average HbA₁ c reduction of 0•2-0•4% and average weight loss of approximately 0•5-1 kg.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Stage 3 diabetes is the onset of clinical disease.

“Stage 3 diabetes is the onset of clinical disease.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Glucose monitoring and nutrition management are foundational pillars of type 1 diabetes care and are essential for glycaemic control and preventing complications.

“Glucose monitoring and nutrition management are foundational pillars of type 1 diabetes care and are essential for glycaemic control and preventing complications.98,99”

• cites [98] Franz, 2017, Academy of Nutrition and Dietetics nutrition practice guideline for type 1 and type 2 diabetes in adults: systematic review of evidence for medical nutrition therapy effectiveness and recommendations for integration into the nutrition care process, J Acad Nutr Diet sourceNot checked — no full text of the source
• cites [99] Annan, 2022, ISPAD Clinical Practice Consensus Guidelines 2022: nutritional management in children and adolescents with diabetes, Pediatr Diabetes sourceNot checked — no full text of the source

May combine two claims.

A fully automated AID system equipped with a meal detection algorithm is considered the ultimate solution to addressing the missed meal insulin boluses, and investigational systems have already shown substantial progress in this field.

“A fully automated AID system equipped with a meal detection algorithm is considered the ultimate solution to addressing the missed meal insulin boluses, and investigational systems have already shown substantial progress in this field.107”

• cites [107] Garcia-Tirado, 2021, Advanced closed-loop control system improves postprandial glycemic control compared with a hybrid closed-loop system following unannounced meal, Diabetes Care sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Adjunctive treatments that pair AID with GLP-1 receptor agonists and SGLT2 inhibitors are being studied with the aim of improving postprandial hyperglycaemia.

“Additionally, adjunctive treatments that pair AID with GLP1 receptor agonists and SGLT2 inhibitors are being studied with the aim of improving postprandial hyperglycaemia.”

Probably not a substantial claim: may not pass S3 (load-bearing).

AID systems automate insulin administration by continuously adjusting insulin doses on the basis of real-time glucose concentrations.

“AID systems automate insulin administration by continuously adjusting insulin doses on the basis of realtime glucose concentrations.”

May combine two claims.

Adjunctive therapies include the amylin analogue pramlintide, metformin, GLP-1 receptor antagonists, and SGLT2 and dual SGLT1 and SGLT2 inhibitors.

“Adjunctive therapies include the amylin analogue pramlintide, metformin, GLP1 receptor antagonists, and SGLT2 and dual SGLT1 and SGLT2 inhibitors.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

People with language barriers will also face challenges in accessing and choosing whether to participate in screening and accept therapy.

“People with language barriers will also face challenges in accessing and choosing whether to participate in screening and accept therapy.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

Pramlintide is the only US FDA-approved adjunctive therapy for type 1 diabetes, reduces glucagon secretion, slows gastric emptying, and promotes satiety.

“Pramlintide, the only US FDAapproved adjunctive therapy for type 1 diabetes, reduces glucagon secretion, slows gastric emptying, and promotes satiety.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Individuals with stage 3 diabetes usually have diabetes-related symptoms and require insulin.

“Individuals with stage 3 diabetes usually have diabetes-related symptoms and require insulin.”

Probably not a substantial claim: may not pass S4 (based).

If payment falls on individuals, affordability will become a major obstacle for people in low-income settings, especially in countries without comprehensive healthcare coverage.

“If payment falls on individuals, affordability will become a major obstacle for people in lowincome settings, especially in countries without comprehensive healthcare coverage.”

Probably not a substantial claim: may not pass S4 (based).

People in underserved or low-income communities are most likely to face challenges accessing screening for islet autoantibodies, disease-modifying therapies, and diabetes technology due to poor healthcare infrastructure, awareness, and insurance coverage.

“People in underserved or lowincome communities are most likely to face challenges accessing screening for islet autoantibodies, diseasemodifying therapies, and diabetes technology due to poor healthcare infrastructure, awareness, and insurance coverage.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Time in tight range (TITR; defined as blood glucose concentration of 3.9-7.8 mmol/L) is an emerging glycaemic metric for optimal glycaemic control.

“Time in tight range (TITR; defined as blood glucose concentration of 3•9-7•8 mmol/L) is an emerging glycaemic metric for optimal glycaemic control.”

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

AID systems do not distinguish between variations in insulin needs caused by stress, illness, or physical activity; however, integrating signals from other wearable devices could help the system make more informed decisions about insulin delivery.

“AID systems do not distinguish between variations in insulin needs caused by stress, illness, or physical activity; however, integrating signals from other wearable devices could help the system make more informed decisions about insulin delivery.”

• AssumptionRests on an assumption: AID systems do not distinguish between variations in insulin needs caused by stress, illness, or physical activity.

Probably not a substantial claim: may not pass S3 (load-bearing).

Glucose-responsive insulins are designed to automatically adjust their activity on the basis of blood glucose concentrations.

“Glucoseresponsive insulins (GRIs), or socalled smart insulins, are designed to automatically adjust their activity on the basis of blood glucose concentrations.”

May combine two claims.

Adjunctive treatments are available to reduce HbA1c and counter adverse outcomes linked to obesity, insulin resistance, and impaired glucagon suppression.

“Adjunctive treatments are available to reduce HbA₁ c and counter adverse outcomes linked to obesity, insulin resistance, and impaired glucagon suppression.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The main concept of GRIs is for the insulin to be released from an in-vivo GRI reservoir during hyperglycaemia and for cessation of insulin release when normoglycaemia is reached.

“The main concept is for the insulin to be released from an invivo GRI reservoir during hyperglycaemia and for cessation of insulin release when normoglycaemia is reached.”

Probably not a substantial claim: may not pass S4 (based).

Subanalyses of trials in individuals with early-stage type 1 diabetes or with stage 3 type 1 diabetes suggest greater efficacy in distinct genetic and phenotypic subgroups.

“Subanalyses of trials in individuals with earlystage type 1 diabetes or with stage 3 type 1 diabetes suggest greater efficacy in distinct genetic and phenotypic subgroups.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Use of pramlintide is limited by the risk of severe hypoglycaemia and injection burden.

“Use of pramlintide is limited by the risk of severe hypoglycaemia and injection burden.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Stage 1 and stage 2 are presymptomatic periods of islet autoimmunity and distinguished by glycaemic criteria.

“Stage 1 and stage 2 are presymptomatic periods of islet autoimmunity and distinguished by glycaemic criteria.”

May combine two claims.

SGLT inhibitors have shown significant reductions in HbA1c of 0.4-0.5%, insulin dose, and bodyweight, without increasing hypoglycaemia risk, although they raise the risk of diabetic ketoacidosis.

“SGLT inhibitors have shown significant reductions in HbA₁ c of 0•4-0•5%, insulin dose, and bodyweight, without increasing hypoglycaemia risk, although they raise the risk of diabetic ketoacidosis.5”

• cites [5] Fralick, 2017, Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor, N Engl J Med sourceNot checked — no full text of the source

May combine two claims.

As a result, glucose concentrations can increase before insulin takes effect, even when meal announcements are made, and AID systems often struggle to maintain postprandial glucose concentrations within the desired range.

“As a result, glucose concentrations can increase before insulin takes effect, even when meal announcements are made, and AID systems often struggle to maintain postprandial glucose concentrations within the desired range.”

May combine two claims.

Insulin icodec is an ultralong-acting, weekly basal insulin with a half-life of approximately 8 days, offers a flat, stable pharmacokinetic profile, low peak-to-trough variation, and consistent glucose-lowering efficacy.

“Insulin icodec, an ultralongacting, weekly basal insulin with a halflife of approximately 8 days, offers a flat, stable pharmacokinetic profile, low peaktotrough variation, and consistent glucoselowering efficacy.”